BioXcel Therapeutics Inc (BTAI)
2.99
+0.15
(+5.13%)
USD |
NASDAQ |
Apr 23, 11:00
BioXcel Therapeutics Free Cash Flow (Quarterly): -26.86M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -26.86M |
| September 30, 2023 | -37.58M |
| June 30, 2023 | -38.23M |
| March 31, 2023 | -52.35M |
| December 31, 2022 | -38.64M |
| September 30, 2022 | -31.19M |
| June 30, 2022 | -33.12M |
| March 31, 2022 | -32.53M |
| December 31, 2021 | -19.94M |
| September 30, 2021 | -20.22M |
| June 30, 2021 | -22.48M |
| March 31, 2021 | -19.96M |
| December 31, 2020 | -20.54M |
| September 30, 2020 | -19.10M |
| Date | Value |
|---|---|
| June 30, 2020 | -14.86M |
| March 31, 2020 | -12.17M |
| December 31, 2019 | -7.921M |
| September 30, 2019 | -7.528M |
| June 30, 2019 | -6.252M |
| March 31, 2019 | -6.27M |
| December 31, 2018 | -4.499M |
| September 30, 2018 | -3.248M |
| June 30, 2018 | -5.09M |
| March 31, 2018 | -1.012M |
| December 31, 2017 | -1.098M |
| September 30, 2017 | -0.322M |
| June 30, 2017 | -0.345M |
| March 31, 2017 | -0.431M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-52.35M
Minimum
Mar 2023
-6.252M
Maximum
Jun 2019
-24.29M
Average
-20.54M
Median
Dec 2020
Free Cash Flow (Quarterly) Benchmarks
| Synlogic Inc | -5.556M |
| Cormedix Inc | -11.04M |
| Bristol-Myers Squibb Co | 3.922B |
| Verastem Inc | -29.68M |
| Ocular Therapeutix Inc | -22.91M |